CD274 and cervical carcinoma: Cancer immunotherapy has received increasing attention from clinical oncologists, and several immune checkpoint inhibitors have shown clinical activity in patients with programmed cell death ligand 1 (PD-L1)-positive cervical cancer (6, 7).